Capital International Investors Has $39.22 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Capital International Investors grew its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 692.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,700,359 shares of the company's stock after buying an additional 3,233,179 shares during the quarter. Capital International Investors owned approximately 2.29% of Neumora Therapeutics worth $39,224,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. State Street Corp lifted its holdings in Neumora Therapeutics by 65.3% during the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company's stock worth $23,655,000 after buying an additional 707,409 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Neumora Therapeutics by 54.0% during the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company's stock worth $26,159,000 after acquiring an additional 694,385 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Neumora Therapeutics by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company's stock valued at $48,466,000 after acquiring an additional 195,142 shares during the last quarter. Swiss National Bank bought a new position in Neumora Therapeutics in the fourth quarter valued at about $1,168,000. Finally, Norges Bank bought a new stake in Neumora Therapeutics during the 4th quarter worth about $1,166,000. Institutional investors and hedge funds own 47.65% of the company's stock.

Wall Street Analyst Weigh In

NMRA has been the subject of a number of analyst reports. HC Wainwright lowered their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. William Blair downgraded Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, March 10th. Needham & Company LLC restated a "buy" rating and set a $5.00 target price on shares of Neumora Therapeutics in a report on Thursday, April 10th. Stifel Nicolaus cut Neumora Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $6.00 to $2.00 in a research note on Friday, March 7th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $4.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $9.29.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock traded up $0.01 during midday trading on Wednesday, reaching $0.71. The stock had a trading volume of 1,530,251 shares, compared to its average volume of 1,479,635. Neumora Therapeutics, Inc. has a 1-year low of $0.62 and a 1-year high of $17.19. The firm's fifty day simple moving average is $1.14 and its 200-day simple moving average is $5.97. The stock has a market capitalization of $114.99 million, a P/E ratio of -0.38 and a beta of 2.89.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, sell-side analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.